172 related articles for article (PubMed ID: 37656760)
1. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density.
Yamamoto S; Kusabuka H; Matsuzawa A; Maruyama I; Yamazaki T
PLoS One; 2023; 18(9):e0290685. PubMed ID: 37656760
[TBL] [Abstract][Full Text] [Related]
2. Selectivity and Maximum Response of Vibegron and Mirabegron for β
Brucker BM; King J; Mudd PN; McHale K
Curr Ther Res Clin Exp; 2022; 96():100674. PubMed ID: 35693456
[TBL] [Abstract][Full Text] [Related]
3. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
Hicks A; McCafferty GP; Riedel E; Aiyar N; Pullen M; Evans C; Luce TD; Coatney RW; Rivera GC; Westfall TD; Hieble JP
J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
[TBL] [Abstract][Full Text] [Related]
4. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells.
Carpéné C; Galitzky J; Fontana E; Atgié C; Lafontan M; Berlan M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):310-21. PubMed ID: 10344530
[TBL] [Abstract][Full Text] [Related]
5. Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat.
Maruyama I; Goi Y; Tatemichi S; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
Naunyn Schmiedebergs Arch Pharmacol; 2012 Aug; 385(8):845-52. PubMed ID: 22552730
[TBL] [Abstract][Full Text] [Related]
6. Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells.
Yanagisawa T; Sato T; Yamada H; Sukegawa J; Nunoki K
Tohoku J Exp Med; 2000 Nov; 192(3):181-93. PubMed ID: 11249148
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of intravenous and intravesical application of vibegron, a β
Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
[TBL] [Abstract][Full Text] [Related]
9. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-guided Virtual Screening to Identify New β
Ujiantari NSO; Ham S; Nagiri C; Shihoya W; Nureki O; Hutchinson DS; Schuster D
Mol Inform; 2022 Jul; 41(7):e2100223. PubMed ID: 34963040
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
Edmondson SD; Zhu C; Kar NF; Di Salvo J; Nagabukuro H; Sacre-Salem B; Dingley K; Berger R; Goble SD; Morriello G; Harper B; Moyes CR; Shen DM; Wang L; Ball R; Fitzmaurice A; Frenkl T; Gichuru LN; Ha S; Hurley AL; Jochnowitz N; Levorse D; Mistry S; Miller RR; Ormes J; Salituro GM; Sanfiz A; Stevenson AS; Villa K; Zamlynny B; Green S; Struthers M; Weber AE
J Med Chem; 2016 Jan; 59(2):609-23. PubMed ID: 26709102
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
[TBL] [Abstract][Full Text] [Related]
14. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Takasu T; Ukai M; Sato S; Matsui T; Nagase I; Maruyama T; Sasamata M; Miyata K; Uchida H; Yamaguchi O
J Pharmacol Exp Ther; 2007 May; 321(2):642-7. PubMed ID: 17293563
[TBL] [Abstract][Full Text] [Related]
15. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice.
Kiso T; Namikawa T; Tokunaga T; Sawada K; Kakita T; Shogaki T; Ohtsubo Y
Biol Pharm Bull; 1999 Oct; 22(10):1073-8. PubMed ID: 10549858
[TBL] [Abstract][Full Text] [Related]
16. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.
Tyagi P; Thomas CA; Yoshimura N; Chancellor MB
Int Braz J Urol; 2009; 35(1):76-83. PubMed ID: 19254402
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and functional characterization of 1-benzyl substituted trimetoquinol affinity analogs on rat and human beta-adrenoceptors.
Mehta RC; Salazar-Bookaman MM; Fertel RH; De Los Angeles J; Nikulin VI; Fraundorfer PF; Miller DD; Feller DR
Biochem Pharmacol; 2000 Mar; 59(5):517-29. PubMed ID: 10660118
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.
Igawa Y; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):177-83. PubMed ID: 23263450
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of pharmacological properties and selectivity of SWR-0315NA for beta3-adrenoceptors.
Ahmed M; Hanaoka Y; Kiso T; Kakita T; Ohtsubo Y; Nagatomo T
Biol Pharm Bull; 2004 May; 27(5):718-22. PubMed ID: 15133253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
